Ten-Year Results Following One-Stage Septic Hip Exchange in the Management of Periprosthetic Joint Infection.


Journal

The Journal of arthroplasty
ISSN: 1532-8406
Titre abrégé: J Arthroplasty
Pays: United States
ID NLM: 8703515

Informations de publication

Date de publication:
06 2019
Historique:
received: 19 11 2018
revised: 30 01 2019
accepted: 13 02 2019
pubmed: 13 3 2019
medline: 21 4 2020
entrez: 13 3 2019
Statut: ppublish

Résumé

Although 2-stage revision is still considered the gold standard for surgical management of periprosthetic joint infection (PJI), 1-stage revision has been reported to be as effective. Long-term reports for 1-stage revision in hip PJIs are lacking. We reviewed our 10-11 years of results of 85 patients who underwent 1-stage exchange of the hip with an antibiotic-loaded bone cemented prosthesis due to PJI to determine the following: (1) What is the infection-free survival? (2) What is the overall survival? and (3) What are the long-term clinical outcomes? All 1-stage revision total hip arthroplasties (THAs) for infection between January 2006 and December 2007, with a minimum 10-year follow-up (range 10-11), were included in this retrospective cohort. Patients from another country or patients who were unable to participate were excluded. Eighty-five patients with a hip PJI were available at the last follow-up. Thirty-seven patients died during the 10-year study. Harris Hip Scores were recorded before the surgery and at last follow-up. Failures are reported as infection-related or aseptic. The 10-year infection-free survival was 94% and the surgery-free survival was 75.9%. The Harris Hip Scores improved from 43 (range 3-91) to 75 (range 10-91) (P < .001). The main indication for re-revision after 1-stage exchange was instability (10/20 patients). One-stage exchange of the hip for PJI is a reliable treatment option with high rate of infection control and long-lasting favorable outcomes.

Sections du résumé

BACKGROUND
Although 2-stage revision is still considered the gold standard for surgical management of periprosthetic joint infection (PJI), 1-stage revision has been reported to be as effective. Long-term reports for 1-stage revision in hip PJIs are lacking.
METHODS
We reviewed our 10-11 years of results of 85 patients who underwent 1-stage exchange of the hip with an antibiotic-loaded bone cemented prosthesis due to PJI to determine the following: (1) What is the infection-free survival? (2) What is the overall survival? and (3) What are the long-term clinical outcomes? All 1-stage revision total hip arthroplasties (THAs) for infection between January 2006 and December 2007, with a minimum 10-year follow-up (range 10-11), were included in this retrospective cohort. Patients from another country or patients who were unable to participate were excluded. Eighty-five patients with a hip PJI were available at the last follow-up. Thirty-seven patients died during the 10-year study. Harris Hip Scores were recorded before the surgery and at last follow-up. Failures are reported as infection-related or aseptic.
RESULTS
The 10-year infection-free survival was 94% and the surgery-free survival was 75.9%. The Harris Hip Scores improved from 43 (range 3-91) to 75 (range 10-91) (P < .001). The main indication for re-revision after 1-stage exchange was instability (10/20 patients).
CONCLUSION
One-stage exchange of the hip for PJI is a reliable treatment option with high rate of infection control and long-lasting favorable outcomes.

Identifiants

pubmed: 30857953
pii: S0883-5403(19)30159-7
doi: 10.1016/j.arth.2019.02.021
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1221-1226

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Akos Zahar (A)

Department of Orthopaedic Surgery, Helios ENDO-Klinik Hamburg, Hamburg, Germany.

Ianiv Klaber (I)

Department of Orthopedic Surgery, Pontificia Universidad Catolica de Chile, Santiago, Chile.

Anne-Marie Gerken (AM)

Department of Orthopaedic Surgery, Helios ENDO-Klinik Hamburg, Hamburg, Germany.

Thorsten Gehrke (T)

Department of Orthopaedic Surgery, Helios ENDO-Klinik Hamburg, Hamburg, Germany.

Matthias Gebauer (M)

Department of Orthopaedic Surgery, Helios ENDO-Klinik Hamburg, Hamburg, Germany; Department of Orthopaedic Surgery, Roland-Klinik Bremen, Bremen, Germany.

Christian Lausmann (C)

Department of Orthopaedic Surgery, Helios ENDO-Klinik Hamburg, Hamburg, Germany.

Mustafa Citak (M)

Department of Orthopaedic Surgery, Helios ENDO-Klinik Hamburg, Hamburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH